Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharming Group NV

www.pharming.com

Latest From Pharming Group NV

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022

The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.

Commercial Companies

Pharming Explores Further Uses For Ruconest

Pre-eclampsia and nephropathy associated with the use of contrast media in cardiac patients are two new potential uses for Pharming’s marketed C1-esterase inhibitor product.

 

Immune Disorders Clinical Trials

Wanted: Orphan Drugs, Antivirals Dominate China's Latest Fast Track List

Half of the newly selected imported drugs slated for fast track review in China are rare disease treatments, followed by antiviral drugs for influenza and HIV, reflecting key medical needs in the country.

Rare Diseases Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Pharming Group NV
  • Senior Management
  • Sijmen de Vries, MD, CEO
    Robin Wright, CFO
  • Contact Info
  • Pharming Group NV
    Phone: (31) 71 5247 400
    Darwinweg 24
    P.O. Box 451 CR Leiden, 2333
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register